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Abstract
Background: Tuberculosis (TB) remains a major cause of morbidity 
and mortality worldwide. Continued surveillance of drug susceptibility 
helps determining proper treatment regimen. This study aimed to 
investigate occurrence, patterns of anti-tuberculosis drug-susceptibility 
at the King Abdulaziz University Hospital (KAUH), Jeddah, KSA.
Methods: This study represents a cross sectional study and including 
a total of 101 TB patients examined in the Clinical and Molecular 
Microbiology Laboratory at the KAUH from January 2013 to June 
2014. They were 43 Saudi and 58 non-Saudi patients. Each specimen 
was digested, decontaminated, and its pellet was used for preparation 
fluorochrome stain. The rest of each pellet was used for culture in 
the VersaTREK liquid culture system as well as used for direct MTBC 
detection by GeneXpert PCR. The susceptibility to anti-TB drugs was 
done by VersaTREK.
Results: The sensitivity of PCR for MTBC detection was 88.1% for 
AFB-positive specimens and 29.9% for AFB-negative ones, while the 
sensitivity of PCT for MTBC detection was 74.3% and 51.9% for 
pulmonary and extra-pulmonary specimens, respectively. VersaTREK 
detection time was 15.01±7.32 and 26.63±6.7 days for positive and 
negative AFB specimens, respectively. The resistance rate to pyrazinamide 
was (13.86%), followed by streptomycin (7.9%), rifampicin (3.96%) and 
isoniazid (3.96%). Mono-resistance rates to pyrazinamide, rifampicin 
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Introduction
Tuberculosis (TB) remains a major cause of 
morbidity and mortality worldwide. The World 
Health Organization(WHO) estimates that one-
third of the population of the world is infected with 
Mycobacterium tuberculosis and that more than 8 
million new cases of active TB occur annually [1]. 
Today, there are two monumental threats to global 
TB control; the HIV epidemic and the increasing 
prevalence of anti-tuberculosis drug-resistance [2].
There are important factors contribute to 
emergence of anti-tuberculosis drug-resistance, 
including treatment with a single drug, inappropriate 
prescription or poor adherence to treatment, 
suppression the growth of susceptible bacilli to 
used drug, while permits the development of drug-
resistant bacilli.  Subsequent transmission of resistant 
TB bacilli from an infectious case to other susceptible 
persons may lead to TB primary resistance [3,4].
The Kingdom of Saudi Arabia (KSA) is among 
the most dynamic immigration hubs on the globe. 
It hosts approximately 8.4 to 10 million expatriates 
and annually receives another 10 million for Islamic 
rituals (Hajj and Umrah) compared to a population 
of 18.7 million nationals. The majority of the visitors 
and expatriates are coming from countries with 
high incidence of TB such as South-East Asia, Indian 
subcontinent and Africa. Many of these foreign-born 
residents and pilgrims reside at least for one-week 
or much longer, in overcrowded and suboptimal 
living conditions, and in constant and close contact 
with Saudi citizens. These factors enhance TB 
transmission among the country population [5]. 
In KSA, the pattern of anti-TB drug resistance 
showed marked regional variation. Analysis of local 
rates of drug-resistance provides the necessity 
of using the four-drug regimen consisting of 
isoniazid (INH), rifampicin (RIF), ethambutol (EMB) 
and pyrazinamide (PZA). Therefore, continued 
surveillance of drugs susceptibility patterns is 
necessary to determine the extent and patterns of 
anti-TB drug resistance in KSA[6]. The solid medium-
based drug-susceptibility testing (DST) method is 
slow and delays the detection of drug-resistance 
M. tuberculosis, increased risks of inappropriate 
treatment and spread of drug-resistant strains. 
These factors have led to the development of newer 
DST methodologies, includinguse of liquid culture 
systems according to recent recommendations of 
WHO [7]. Additionally, several direct techniques for 
DNA amplification of M. tuberculosisfrom in sputum 
have received approval by the US Food and Drug 
Administration (FDA). However, most of these rapid 
tests, do not provide full information about anti-TB 
drug-susceptibility [8].
and isoniazid were 11.88%, 1.98% and 0.99%, respectively. MDR-TB 
were 1.98%, and there was no significant difference between Saudi 
and non-Saudi TB patients regarding the resistance to anti-TB drugs.
Conclusion: Further studies and continued surveillance of the drug 
resistance patterns of M. tuberculosis are needed to reduce risk factors 
of infection with MDR-TB, and to formulate effective chemotherapy 
in the management of TB cases.
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The present study aims to investigate the role 
of PCR for the rapid detection of MTBC directly in 
clinical samples as compared to the liquid culture 
(VersaTREK), and to determine the pattern of anti-
TB drug-resistance at the King Abdulaziz University 
Hospital, Jeddah.
Materials and Methods 
This prospective cross-sectional study was done in 
the Clinical and Molecular Microbiology Laboratory 
at the King Abdulaziz University Hospital (KAUH), 
Jeddah, KSA from January 2013 through June 2014.
Ethical consideration
The study was approval by Research Ethics 
Committee, and the Unit of Biomedical Ethics, 
Faculty of Medicine, King Abdulaziz University 
(Reference Number: 241-15).
This study was included 101 patients diagnosed 
with TB. All patients were subjected to full history 
taking, full clinical examinations with radiological 
and routine laboratory investigations. 
Preparation of Specimens
Each specimen was digested and decontaminated 
by ready to use N-acetyl-l-cysteine (NALC) 3% 
NaOH method (Nac-PACTMEA3, Alpha Tec, Inc, 
Vancouver, Washington, USA) as described by the 
manufacturer [7]. Part of the obtained pellet of each 
specimen was used for detection of M.tuberculosis 
Complex (MBTC) by preparing a smear using 
fluorochrome stain (Fluo-RAL-Auramine staining kit 
for Mycobacteria Detection (RAL-automated staining 
system-R.A.L. instruments, Montesquieu-33650 
MARTILLAC-France), and later each smear was 
examined with the fluorescent microscope. The 
rest of the pellet was used for culture in the 
VersaTREK liquid culture system as well as for direct 
MTBC detection by GeneXpert PCR (Cepheid 904 
Caribbean Drive Sunnyvale, CA 94089-1189-USA).
The GeneXpert Dx System (Cepheid 904 
Caribbean Drive Sunnyvale, CA 94089-
1189-USA) 
The GeneXpert Dx System integrates and 
automates sample processing, nucleic acid 
amplification, and detection of the target sequences 
of simple or complex samples using real time PCR 
and reverse transcriptase PCR.
Molecular detection of MTBC and rpoB gene 
mutations associated with rifampicin-resistance 
speeds the detection of MDR-TB. The Xpert MTB/
RIF assay can be used on fresh samples as well as 
on prepared sediments [8].
a) Sample sediment procedure: Each MTB/RIF 
cartridge was labeled by the sample ID, then 1 ml 
of the total re-suspended pellet was transferred to a 
conical screw-capped tube for the Xpert MTB/RIF by 
a pipette, followed by a transfer of 2 ml of the Xpert 
Sample Reagent (SR) to the re-suspended sediment, 
then vortex for 10 seconds was done.The conical screw-
capped tube was incubated for 10 minutes at room 
temperature, then vortex was done and re-incubated 
for additional 5 minutes.The liquefied sample was 
transferred to the sample chamber of the Xpert MTB/
RIF cartridge and the cartridge was loaded into the 
GeneXpert Dx Instrument. The test was started and 
the running software was GX 4.0 [8].
b) Sample preparation and extraction of 
nucleic acids: The GeneXpert System completely 
integrates and automates the sample preparation 
and performs all the complex steps of nucleic acid 
extraction in its advanced microfluidic cartridge [8].
c) Amplification of the extracted nucleic 
acids: The GeneXpert System modules performed 
rapid heating and cooling cycles required for highly 
reliable real-time PCR in the reaction tube of the 
cartridge [8].
d) Detection of a target gene sequence: The 
GeneXpert System, s multiple optics can detect the 
THE INTERNATIONAL ARABIC JOURNAL OF ANTIMICROBIAL AGENTS
ISSN 2174-9094
2015
Vol. 5 No. 3:2
doi: 10.3823/774
4   This article is available from: www.iajaa.org  /  www.medbrary.com 
presence of multiple target nucleic acids in the same 
cartridge [8].
e) Interpretation of Results: The GeneXpert 
System generated the results from measured 
fluorescent signals and embedded calculation 
algorithms. The detection of MTBC (very low, low, 
medium, or high) was dependent on the number 
of the TB bacilli in the sample [8].
Inoculation of VersaTREK528 (Trek 
Diagnostic Systems, Inc. Westlake, Ohio, 
USA)
Bottle Preparation and Inoculation (Remel™ 
Oxoid™VersaTREK and Sensititre™ products) was 
done as recommended in MB/BacT Detection system 
manual; http://www.biomerieux.com [9].
Classification of positive isolates by The 
Gene Xpert Dx system (Cepheid 904 
Caribbean Drive Sunnyvale, CA 94089-
1189-USA) 
A total of 1 ml of each positive culture bottle 
was used for detection of MTBC and a rpoB gene 
mutations associated with RIF resistance.
Susceptibility testing for Anti-TB drugs by 
VersaTREK (Remel™ Oxoid™ VersaTREK and 
Sensititre™ products)
a) Preparation of anti-tuberculous drugs: 
Rifampicin, isoniazid, ethambutol, streptomycin 
and pyrazinamide were reconstituted according to 
manufacturer’s instructions. A total of 1.0 ml of the 
positive culture was taken and 9.0 ml of distilled 
water was added and vortex was done, then 0.5 
ml of this diluted positive culture was used for 
inoculation of each mycobroth bottles.
b) Sensitivity by Myco-Susceptibility kit: 
Eight new Mycobroth bottles were prepared 
for each positive MBTC culture according to 
manufacturer’s instructions [9].
c) Sensitivity for Myco-Pyrazinamide (PZA) 
Kit: Two Myco broth bottles were prepared 
according to manufacturer’s instructions [9].
d) Results Interpretation: The isolate in a 
drug-containing bottle is considered to be resistant 
when its time for detection is equal to, or within 
three days from the detection time of the drug-free 
control bottle [9].
Statistical analysis 
Data were analyzed using Statistical Package 
for Social Sciences (SPSS) software, version 18. Chi 
square test was utilized to test for the association 
and/or difference between categorical variables. 
Fisher exact test was used when appropriate. 
Continuous variables were presented as mean, 
standard deviation and range. Student t test was 
used to compare between two groups. P value less 
than 0.05 was considered statistically significant.
Results
The present study includes a total of 101 
confirmed infected patients with TB. They were 
43(42.5 %) Saudis, their ages ranged from 14 to 
39 years with a mean ± SD (23.37± 14.31 years), 
and 26 (60.4%) of them were males and 17(39.6%) 
were females. The second group of the TB patients 
were 58 (57.5 %) non-Saudi, their ages ranged from 
1 to 92 years with a mean ± SD (40.3± 12.6 years), 
and 18 (48.3%) of them were males and 40(51.7%) 
were females. Clinical samples were collected from 
various clinical units of KAUH (Table 1).  
The sensitivity of GeneXpert PCR for the 
detection of MTBC in sputum, tracheal aspirate, 
bronchial wash, CSF, cyst, tissue, gastric aspirate 
and peritoneal fluid were 81.1%, 40%, 72.7%, 
60%, 85.7%, 36.4%, 0.0% and 50 % respectively 
(Table 2).
The sensitivity of Gene Xpert PCR for the 
detection of MTBC was 29.4% in AFB-negative and 
88.1% in AFB-positive samples while, the sensitivity 
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Table 1. Demographic characteristics of 101 patients*
Parameters No. (%) Saudi No. (%) Non-Saudi Test of significance P-value
Age 
range 14-39 1-92
t=.99 0.955
Mean ±SD 23.37±14.31 40.3±12.6
Sex 
Males
Females
26 (60.4)
17 (39.6)
18 (48.3)
40 (  51.7)
X2 = 1.45 0.235
Hospital Ward 
Isolation unit
Other units
22 (51.2)
21 (48.8)
31 ( 53.4)
27 ( 46.6)
X2 = 0.05 0.48
*No of Saudi patients (43) and non-Saudi patients (58).
were 80%,87.5%,77.8% and 100% in AFB +1,+2,+3 
and+4 positive samples, respectively (Table 3).
The sensitivity of GeneXpert PCR for the detection 
of MTBC in all AFB-negative and positive pulmonary 
and extra-pulmonary specimens are shown in 
Table 3. 
The detection time of MTBC by VersaTREK 
was shorter in AFB-positive than in AFB-negative 
samples (15.01±7.32 vs  26.63±6.7 days) (Table 4). 
Moreover, the detection time of AFB-positive was 
comparable in both pulmonary and extra-pulmonary 
specimens (Table 4).
All anti-TB drug resistance detected in our 
study was primary resistance (resistance among 
newly diagnosed cases with no previous history of 
treatment with anti-TB drugs or treatment for less 
than one month.
The resistance to pyrazinamide was the most 
common type of resistance (13.86%), followed 
by the resistance to streptomycin (7.9%), 
rifampicin (3.96%) and INH (3.96%). Mono-
resistance to pyrazinamide, rifampicin and INH 
were 11.88%,1.98% and 0.99%, respectively. 
Meanwhile, MDR-TB accounted to 1.98%, and the 
rate of any drug resistance was 24.75%. There was 
no significant difference between Saudi and non-
Saudi TB patients regarding any type of resistance 
to anti-tuberculous drugs (Table 5).
Discussion
The worldwide increase in the rates of multidrug-
resistant (MDR) tuberculosis (resistance to at least 
rifampicin and isoniazid) has made the timely 
identification of resistant MTBC strains an important 
emergence to achieve effective disease management 
and to prevent their spread in community. INH and 
RIF are the most important first-line anti-tuberculosis 
drugs, and resistance to these drugs are often 
associated with treatment failure and fatal clinical 
outcome [10].
This study found no significant differences 
between Saudis and non-Saudi TB patients 
regarding the age, sex, incidence or hospitalization 
in different unints (Table 1). This observation was 
not compatible with results obtained by Abouzeid 
et al.[11] in their 10-year retrospective study, where 
non-Saudis had nearly twice the TB incidence rate 
compared to Saudis. Our result may be explained 
by the size of our patients, sample which was small 
to reveal a statistically significant data.
This study shows that the rate of male patients 
was higher than that of females (60.4% vs. 39.6%) 
among Saudi patients with no significant difference. 
This result might be due to the higher occupational 
exposure of males to droplet infections together 
with some other factors such as smoking. Also, 
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Table 2. AFB staining results and MTBC detection by Gene Xpert in each specimen.
Types (No. ) of specimens 
examined
No. (%) AFB staining results
Detection of MTBC by PCR
Detected
No.69(%)
Not detected
No.32 (%)
Sputum (53) Total sputum 53 (100) 43(81.1) 10(18.9)
AFB –ve   9(17) 4(44.4) 5(55.6
AFB +ve   44(83) 39(88.6) 5(11.4)
+1   10(18.9) 7(70) 3 (30)
+2   5(9.4) 5(100) 0 (0.0)
+3   7(13.2) 5 (71.4) 2(28.6)
+4   22 (41.5) 22(100) 0 (0.0)
Tracheal aspirate (10) Total TA 10(100) 4(40) 6(60)
AFB –ve   4(40) 0  (0.0) 4(100)
AFB +ve   6(60) 4(66.6) 2(33.3)
+1   5(50) 3 (60) 2(40)
+3   1 (10) 1(100) 0(0.0)
Bronchial wash (11) Total BW 11(100) 8 (72.7) 3 (27.3)
AFB –ve 3(27.3) 0 (0.0) 3(100)
AFB +ve 8(72.7) 8(100) 0(0.0)
+1 5(45.5) 5(100) 0(0.0)
+2 2(18.2) 2(100) 0 (0.0)
+3 1(9.1) 1(100) 0(0.0)
CSF (5) Total  CSF - ve 5(100) 3(60) 2(40)
Cyst (7) Total Cyst 7(100%) 6(85.7) 1(14.3)
- ve 3(42.9) 2(66.7) 1(33.3)
+1 1(14. 3) 1(100) 0(0.0)
+4 3(42.9) 3(100 ) 0(0.0)
Tissue (11) Total Cyst 11(100) 4(36.4) 7(63.6)
- ve 8 (72.7) 1(12.5) 7(87.5)
+1 3(27.3) 3 (100) 0(0.0)
Gastric aspirate (2) Total GA 2(100) 0(0.0) 2(100)
- ve 1(50) 0(0.0 ) 1(100)
+2 1 (50) 0(0.0) 1(100)
Peritoneal fluid (2) Total PTF 2(100) 1(50) 1(50)
-ve 1(50) 0(0.0) 1(100)
+1 1 (50) 1(100) 0(0.0)
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traditional costumes of females in Saudi Arabia 
with covering their faces by (Hijab) may reduce 
the incidence of exposure to droplet infections. 
Gender distribution was similar to the studies of 
Erbes et al. [12], and the study of Al shimemeri 
et al. [1] has indicated that males were diagnosed 
more often with severe pulmonary tuberculosis 
than females.
The present study found that AFB-positive 
sputum samples were representing 83%of total 
sputum samples, and were divided into 18.9% (+1), 
9.4% (+2) and 13.2% (+3) (Table 2). While Khatib 
et al. [13] discovered that (28.6%) of the sputum 
samples were +2 followed by (23.8 %) as +1 and 
(17.1%) as +3.
The sensitivity of PCR MTBC detection was 29.4% 
and 88.1% in positive and negative AFB samples, 
respectively (Table 3). Our results were less than 
those of Ioannidis et al. [14] and Mishra et al. [15] who 
reported that the sensitivity of PCR for MTBC detection 
of AFB-positive samples were 100% and 96.4%, 
respectively. Our findings regarding PCR detection 
of MTBC in AFB-negative samples did not correlate 
well with those reported by others [16,17], since their 
studies were performed mainly on respiratory samples. 
Also, the higher sensitivity for AFB-negative specimens 
in those studies were obtained following using more 
than one specimen for each patient. The sensitivity 
of PCR for MTBC detection of total pulmonary, AFB-
positive and AFB-negative pulmonary samples were 
Table 3.  MTBC detection  of AFB-negative, AFB-positive, pulmonary and extra-pulmonary specimens by 
Gene Xpert
AFB staining results (no.)
Detection of MTBC by PCR
No.(%)Detected No. (%)Not detected
AFB-negative (34) 10(29.4) 24 (70.6)
AFB-positive (67) 59(88.1) 8(11.9)
AFB+1 (25) 20 (80) 5 (20)
AFB +2 (8) 7 (87.5) 1 (12.5)
AFB +3 (9) 7 (77.8) 2 (22.2)
AFB +4 (25) 25 (100) 0 (0.0)
Total pulmonary specimens (74) 55 (74.3) 19( 25.7)
AFB-ve pulmonary specimens (16)  4(25)  12(75)
AFB +ve pulmonary specimens (58)  51(87.9)  7(12.1)
Total extra-pulmonary specimens (27)  14(51.9)  13(49.1)
AFB-ve extra-pulmonary specimens (18)   6(33.3) 12(66.7)
AFB +ve extra-pulmonary specimens (9) 8   (88.8%) 1(11.2)
Total  samples (101) 69 (68.3) 32 (31.7)
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Table 4. Detection time of MTBC by VersaTREK according to AFB staining results.
Types of specimen (No.) AFB staining (No.) *
Detection time (days) by Versa TREK 
(Mean±SD)
Sputum (53)
- ve(9) 26.66 ± 6.32
+1(10) 21.33 ± 4.84
+2(5) 14.6.33 ± 4.39
+3(7) 15.8 ±7.9
+4(22) 11.52 ± 5.61
Tracheal aspirate (10)
- ve(4) 27.75± 7.93
+1(5) 21.61 ± 5.77
+3(1) 7
Bronchial wash (11)
- ve(3) 27.33 ± 11.71
+1(5) 20.66 ± 8.36
+2(2) 10.5 ± 0.701
+3(1)  7
Cerebrospinal fluid (5) - ve(5) 23 ± 2.7
Cyst (7)
- ve(3)  25.66 ± 6.65
+1(1) 21
+4(3)  13 ± 1.41
Tissue (11)
- ve(8) 28.28 ± 8.67
+2(3) 24.33 ± 10.4
Gastric aspirate (2)
- ve(1) 26
+2(1) 15
Peritoneal fluid (2)
-ve(1) 30
+1(1) 24
Total AFB (67) +ve 15.01±7.32
Total AFB (34) -ve 26.63±6.7
*–ve= negative; +ve= positive.
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74.3%, 87.9% and 25%, respectively (Table  3). 
Zeka et al. [18] reported that the sensitivity of PCR 
for pulmonary specimens were 74.2% and 100% for 
both of negative and positive specimens, respectively. 
While Omrani et al. [19] reported also that, 23.5% 
of their AFB-negative pulmonary TB samples were 
detected by PCRin their study in the Prince Sultan 
Military Medical City, Riyadh, KSA .
This study demonstrates that the sensitivity of 
PCRfor MTBC detection of total pulmonary, AFB-
positive and AFB-negative extra-pulmonary samples 
were 51.9%, 88.8% and 33.3%, respectively (Table 
3), while the study of Zeka et al. [18] reported 
sensitivity of 63% and 100% for negative and 
positive specimens, respectively. Omrani et al. [19] 
reported also that 24.4% of AFB-negative extra-
pulmonary TB samples included in their study were 
detected by PCR.
In the current study, the detection time of MBTC 
by VersaTREK for AFB-positive samples (15.01±7.32 
days) was shorter than that reported by Falconi et 
al. [20] who observed that primary isolation of M. 
tuberculosis from smear-positive sputum samples 
was 19.8 ± 11.2 days.   However, the detection 
time of smear-positive pulmonary samples was 
comparable to that of extra-pulmonary samples 
in our study (Table 4). Zeka et al. [18] found that 
the median time for smear-positive samples was 
statistically shorter for pulmonary specimens than 
in extra-pulmonary specimens. This finding could 
be due to low number of organisms in the extra-
pulmonary specimens. 
The present study shows that 24.75% of M. 
tuberculosis isolates were found to be resistant 
to one or more of anti-TB drugs (Table 5). This 
percentage was higher than that reported by the 
WHO in 2006 and 2007 (10.2%) [3]. However, other 
studies revealed that the rates of resistance of M. 
tuberculosis isolates in Saudi Arabia were similarly 
high as demonstrated in our study [21,22]. Alrajhi 
Table 5. Anti-tuberculous drug resistance patterns of MTBC in Saudi and non-Saudi TB patients.
Pattern of Anti-TB drugresistance
Total no.(%) 
resistance
Saudis*No. (%) Non-Saudis* No. (%) P- value
Any resistance to RIF 4(3.96 ) 3(75 ) 1(25 ) 0.206
Anyresistance to INH 4(3.96 ) 2(50 ) 2(50 ) 0.57
Anyresistance to PZA 14(13.86 ) 6(42.9 ) 8(59.1 ) 0.61
Anyresistance to Streptomycin 8(7.9 ) 2(25 ) 6(75 ) 0.25
MDR (RIF+INH) 2(1.98 ) 1(50 ) 1(50 ) 0.62
Mono resistance to RIF 2(1.98 ) 2(100 ) 0(0.0 ) 0.17
Mono resistance to INH 1(0.99 ) 0 (0.0 ) 1(100 ) 0.57
Mono resistance to PZA 12(11.88 ) 4(33.3 ) 8(66.7 ) 0.49
Mono resistance to Streptomycin 7(6.93 ) 1(14.3 ) 6(85.7 ) 0.11
Any drug resistance 25(24.75 ) 9(36 ) 16(64 ) 0.29
One drug resistance 22(21.78 ) 7(31.8 ) 15(68.2 ) 0.24
Two drugs resistance 3(2.97 ) 2(66.7 ) 1(33.3 ) 0.47
Four drugs resistance 1(0.99 ) 1(100 ) 0(0.0 ) 0.24
No drug resistance 76(75.25 ) 34(44.7 ) 42 (55.3 ) 0.29
*No of Saudi patients (43) and non-Saudi patients (58).
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and Al-Barrak [21] showed in their meta-analysis of 
previous local studies which based on 12 reports 
from several regions of the Kingdom a wide range 
of resistance from 8.7 to 43.7%. Lower rates of 
resistance have also been reported from two other 
countries in the region (Qatar and Oman) as well 
as from countries with low TB incidence such as 
Western Europe and North America [3]. Other 
Middle East Arab countries such as Lebanon and 
Egypt, reported higher levels of drug-resistant TB 
and MDR-TB [22,23]. Much higher resistance rates 
were also reported from TB-endemic countries of 
South Asia and South-East Asia [3].
This study shows that the PZA resistant strains 
(13.86%) among M. tuberculosis isolates was high. 
Following further identification of these strains using 
Hain PCR method revealed that 12 out of 14 PZA 
resistant strains were M. canetti which are known to 
be intrinsic resistant to PZA, and M. canetti is a novel 
pathogenic taxon of the M. tubcerculosis. The next 
highest resistance was observed with streptomycin 
(7.9%) followed by similar rates of resistance to both 
rifampicin and INH (3.96%) (Table 5).
In KSA, the resistance rates to isoniazid in 
Riyadh, ranged from 4.2 to 7.2% [24,25]. Similar 
resistance rates of about 6% were reported in 
both Dammam [25] and in Taif [26]. A higher 
resistance rates (10.3 to 28.7%) were reported in 
Jeddah [27,28], and the highest rate of resistance 
(41%) was reported from Jazan and was attributed 
to the proximity ofJazan to the Republic of Yemen 
[29]. Additionally, rifampicin-resistance rate was 
low (3.96%), and is similar to the low rifampicin-
resistance rate reported from Dammam [25], 
where as higher rates of rifampicin-resistance were 
reported from Riyadh (9%) [24], Jeddah (5.1 to 
23.4%) [4,27] and Taif (15.3%) [26]. 
This study shows that streptomycin-resistance 
of M. tuberculosis was 7.9%, while the study 
from Riyadh, found 8.8% streptomycin-resistance 
[30],and higher resistance rates were reported from 
Taif (15.9%) [26] and Jeddah (22.7%) [29]. 
Ethambutol-resistance has also been reported to 
be variable in Saudi Arabia, but it was null in our 
study. The same result was reported in Dammam 
[25], while other studies demonstrated higher 
results of resistance (1.3 to 6.9%) in Jeddah [4,27] 
and each 4% in both Taif [26] and Jazan [30]. 
According to our DST results, two isolates 
(1.98%) were detected as MDR strains (Table  5).
The rate of MDR-TB in Saudi Arabia is relatively 
low and variable between Saudi provinces .The first 
representative national survey conducted in Saudi 
Arabia by Al-Hajoj et al. [31], and which included 
all patients diagnosed with culture-positive TB, 
found that the highest proportion was detected in 
Northern provinces (9.19%) and the second highest 
proportion was found in Southern provinces (5.4%), 
followed by Western provinces (4.9%) and Central 
provinces (3.8%). The lowest proportion of MDR-
TB isolates was reported from the Eastern province 
(1.1%). On the other hand, a very high rate of MDR-
TB was reported from Jazan, where the resistance 
rate reached 44% [30]. 
The variability in the resistance rates of tuberculosis 
in Saudi Arabia is dependent on the time and 
location of the study as well as on the numbers 
of non-Saudi patients in each study [32]. In our 
study, the rates of resistance to pyrazinamide and 
streptomycin were higher among non-Saudis than in 
Saudis with no significant difference. Also, the rates 
of mono-resistance to INH, PZA and streptomycin 
were higher in non-Saudis than in Saudis with no 
significant difference (Table 5). These results were 
compatible with that obtained by Al-Tawfiq et al. 
[33] during their 15-year study (1989- 2003) in Saudi 
Aramco Medical Services Organization in Dhahran. 
Our result matched also with that of Varghese et 
al.[34] who reported no significant differences of 
drug- resistance rate between immigrants and local 
population in Saudi Arabia. Therefore, screening 
of expatriate workers and illegal immigrants into 
the Kingdom might help to control spread of TB 
infection. The Ministry of Health of the KSA has 
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implemented such a plan and its effects will be 
evaluated over the next few years [34].
In conclusion, this study found that the rate of 
MTBC detected by PCR was higher in positive than 
negative AFB, and generally low rates of resistance 
were found against all anti-TB drugs. There was 
no significant difference between Saudi and non-
Saudi TB patients regarding any type of resistance 
to anti-TB drugs. Further studies on incidence of 
TB and continued surveillance of resistance pattern 
of M. tuberculosis isolates are needed to formulate 
effective plans for the future management of TB.
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